Recent studies involving humans have indicated that L-α-lysophosphatidylinositol, a GPR55 agonist, induced endothelium-dependent vasorelaxation in the pulmonary arteries (134) and mediated ovarian carcinoma cell-induced angiogenesis (135). Here, GPR55 is linked to ovarian carcinoma.